It is suggested that these under- and overestimations of HER1 expression using radiolabeled anit-HER1 antibodies could be due to different tumor models with different receptor turnover rates, vascular density, permeability, dosing and pharmacokinetics (long presence in blood and penetration ability of antibodies) [52,126,128]. The gene discussed is EGFR; the disease is neoplasm.